Page 27 - Human Use News Today

For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18,...

For too long, significant data gaps around the use of medicinal products during pregnancy and breastfeeding have impeded healthcare decision-making. This lack of information is...

KEYTRUDA now approved for 26 indications in the EU, including seven in gastrointestinal cancers ...

European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth ...

Merck announced today that the European Commission has approved two new indications for Keytruda in the treatment of gastrointestinal cancers. The first concerns the combination of Keytruda with...

Granules continuously manufactured under GMP conditions in fluidized bed process: IPC - a Glatt group company - can manufacture your products

Here are the top three performers on the S&P 500 last week. The big catalyst last week was the Federal Reserve's decision not to raise interest rates for the third straight meeting.

NORTHAMPTON, MA / ACCESSWIRE / December 18, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportEthics and ComplianceIntegrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in...

Takeda TSE4502NYSETAK today announced the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy after stabilization with intravenous immunoglobulin therapy IVIG.

If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous…